CD8A and rheumatoid arthritis: RA patients on effective long-term tocilizumab therapy in our study are characterized by normal Treg numbers, increased Th2 and Th17 cell proportion, and by decreased frequencies of CD8 and naive (both CD4+ and CD8+) cells.